前列腺癌中α比β更多？ - Suppr

Suppr

超能文献

More α Than β for Prostate Cancer?

作者信息

Fendler Wolfgang P, Cutler Cathy

机构信息

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; and.

出版信息

J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21.

DOI:10.2967/jnumed.117.198333

PMID:28935836

Abstract

摘要

相似文献

More α Than β for Prostate Cancer?

J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21.

The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3. doi: 10.1007/s00259-010-1707-7.

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

Cancer Res. 2011 Feb 1;71(3):1009-18. doi: 10.1158/0008-5472.CAN-10-1186. Epub 2011 Jan 18.

Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):363-70. doi: 10.1016/j.ijrobp.2009.10.035.

The Future of Radioligand Therapy: α, β, or Both?

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13.

Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.

Acta Oncol. 2018 Jul;57(7):883-894. doi: 10.1080/0284186X.2018.1433874. Epub 2018 Feb 6.

Comments on "Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer".

Phys Med Biol. 2005 Mar 21;50(6):L1-4; author reply L5-8. doi: 10.1088/0031-9155/50/6/l01.

Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.

Anticancer Res. 2016 Jan;36(1):103-9.

Therapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters.

J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825.

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7.

引用本文的文献

Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?

EJNMMI Radiopharm Chem. 2023 Oct 12;8(1):27. doi: 10.1186/s41181-023-00211-5.

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

Oncologist. 2023 May 8;28(5):392-401. doi: 10.1093/oncolo/oyac279.

Alpha Radiation as a Way to Target Heterochromatic and Gamma Radiation-Exposed Breast Cancer Cells.

Cells. 2020 May 8;9(5):1165. doi: 10.3390/cells9051165.

Alpha-PET for Prostate Cancer: Preclinical investigation using Tb-PSMA-617.

Sci Rep. 2019 Nov 28;9(1):17800. doi: 10.1038/s41598-019-54150-w.

Development of Targeted Alpha Particle Therapy for Solid Tumors.

Molecules. 2019 Nov 26;24(23):4314. doi: 10.3390/molecules24234314.

Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.

Radiol Med. 2018 Dec;123(12):952-965. doi: 10.1007/s11547-018-0929-9. Epub 2018 Aug 16.

An Overview of Targeted Alpha Therapy with Actinium and Bismuth.

Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.

J Nucl Med. 2018 Jul;59(7):1020-1027. doi: 10.2967/jnumed.117.204651. Epub 2018 Mar 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验